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Long-term stable mixed chimerism (MC) is a rare phenomenon after hematopoietic stem cell transplantation
(HSCT) characterized by 5% to 95% residual recipient hematopoietic cells. The underlying mechanisms of MC
are largely unknown. In this study we compared full donor chimerism with long-lasting stable MC for
a median of 9.5 years (range, 5 to 16.5) post-HSCT in patients with nonmalignant diseases. Several factors
signiﬁcantly associated with the likelihood of stable MC development were identiﬁed by univariate analysis,
eg, younger donor age, sibling donor, and conditioning regimen. Despite a limited patient cohort, our
multivariate analysis could conﬁrm that a sibling donor was associated with stable MC development.
Furthermore, development of acute-graft-versus-host disease and blood stream infection was signiﬁcantly
more prevalent in the full donor chimerism patient group. Additionally, signiﬁcant ﬂuctuations in the
recipient-to-donor chimerism ratio decreased over time after HSCT in MC patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION been followed-up for only short periods of time post-HSCT.
Hematopoietic stem cell transplantation (HSCT) is an
established curative treatment for a variety of metabolic and
genetic disorders, leukemia, and other hematologic disorders
[1]. After successful HSCT, the majority of patients adopt the
donor hematopoietic system within months, ie, developing
a full hematopoietic donor chimerism (DC). However,
some patients display residual recipient hematopoietic
cells and develop an intermediate period of hematopoietic
mixed chimerism (MC). A patient is generally considered
to have MC when 5% to 95% hematopoietic cells of recipient
origin remain [2]. It is possible to display MC for only certain
speciﬁc cell subsets, eg, T or B lymphocytes [3-5]. The mech-
anisms directing hematopoietic recovery to MC in some
patients and to DC in others are poorly understood.
The occurrence of MC in a patient could be an indicator of
graft rejection or relapse of underlying disease, even though
these events are not observed in all patients [3,6]. Stable MC,
even for a prolonged time period of up to 3 years, has been
observed in nonmalignant patients alive and well post-HSCT
[7-9]. One study has reported long-term stable MC after
amedian of 12 years inmalignant patients [10]. Furthermore,
stable mixed donor-donor chimerism, a special variant of MC
after double cord blood transplantation, has also been
observed for both short and long time post-HSCT [11,12].
However, in most studies, nonmalignant MC patients haveedgments on page 843.
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13.02.015Here, we retrospectively followed-up 12 patients with
stable MC ranging from 5 to 16.5 years post-HSCT to gain an
insight of possible regulating factors. As controls, we included
13 DC patients matched for age, gender, diagnosis, and time
post-HSCT. To our knowledge, this is the ﬁrst in-depth anal-
ysis of long-term stable nonmalignant MC patients.
We identiﬁed several common factors increasing the
likelihood of stable MC development in patients with
nonmalignant disease after HSCT. In addition, we demon-
strated that ﬂuctuations in the recipient to donor chimerism
ratio decreased over time post-HSCT.
MATERIALS AND METHODS
Patients
Twelve patients who developed MC after HSCT, due to nonmalignant
disease, underwent transplantation at Karolinska University Hospital,
Huddinge, Sweden, between 1996 and 2007 were included in the study.
Patients identiﬁed with DC, with a follow-up of at least 5 years, time post-
SCT and transplanted during the same time period, were selected as
matched controls. Analysis showed that no signiﬁcant difference between
MC and DC groups was found regarding gender, age, and diagnosis. Detailed
patient characteristics can be found in Table 1. Patients are identiﬁed by
their unique patient number (UPN). This study was approved by the
Regional Ethical Review Board in Stockholm, Sweden (2010/1496-31/3).
Chimerism Analysis
Chimerism analysis of peripheral blood samples was performed for all
patients at regular intervals post-HSCT. The cell lineages analyzed were
T lymphocytes (CD3), B lymphocytes (CD19), and myeloid cells (CD33).
From 1997 to 2001, chimerism analyses were based on variable number
tandem repeats, as described previously [13]. Since 2001, chimerism anal-
yses were based on short tandem repeats [14]. Additionally, since 2005,
increasingly more chimerism analyses were done by real-time polymerase
chain reaction (PCR), based on single nucleotide polymorphisms, as
described previously [15]. Full DC was deﬁned as >95% donor-derived cells
in all lineages. MC was deﬁned when >5% but <95% donor-derived cells
were present in at least 1 cell lineage.Transplantation.
Table 1
Patient Characteristics
Chimerism
Status
HSCT
Year
Age at HSCT
(REC/DON)
Gender
(REC/
DON)
Diagnosis Treatment Donor
Type
Stem Cell
Source
Anti T-cell Antibody
Treatment
Conditioning
Treatment
SCT Outcome Immuno-
suppression
Lansky/
Karnofsky
UPN
Mixed
chimerism
1996 21/18 M/M SAA RIC Sibling BM Thymoglobuline Cy Alive and well Yes 90 527
1996 3/5 F/M SAA RIC Sibling BM ATG-Fresenius S Cy Alive and well No 100 539
1997 5/28 M/M AGU MAC MUD PB Orthoclone OKT-3 fTBIþCy Alive and well No 100 603
1997 14/6 M/F SAA RIC Sibling BM Orthoclone OKT-3 Cy Alive and well No 100 615
1998 7/1 F/F b-thalassemia
major
MAC Sibling CBþBM Thymoglobuline BuþCy Alive, low-grade hemolytic
anemia
Yes 90 652
2000 22/25 M/M SAA RIC Sibling BM Thymoglobuline Cy Alive and well No 100 906
2002 9/12 F/M SAA RIC Sibling BM Thymoglobuline Cy Alive and well No 100 921
2004 11/50 F/M Fanconi anemia RIC MUD BM Thymoglobuline FluþCy Alive, pharmacologically
treated depression
No 100 1012
2005 13/2 M/F b-thalassemia
major
MAC Sibling BM Thymoglobuline BuþCy Alive, insulin-dependent
diabetes
No 100 1098
2005 8/0 M/F Fanconi anemia RIC MUD CB Thymoglobuline FluþCy Alive and well No 90 1112
2007 16/19 F/F CGD RIC Sibling BM Thymoglobuline FluþTreo Alive and well No 90 1208
2007 6/6 F/F b-thalassemia
major
MAC Sibling BM - BuþCy Alive and well No 90 1240
Donor
chimerism
1998 1/30 M/M WAS MAC MUD BM ATG-Fresenius S BuþCy Alive, obesity No 90 628
2000 40/29 M/M ALD RIC MUD BM Thymoglobuline Flu Alive, colostomy, urinary
bladder dysfunction and
Addison’s disease
No 80 707b
1999 9/42 F/M SAA RIC MUD BM Thymoglobuline fTBIþCy Alive and well No 100 731
2001 2/17 M/F Sickle cell anemia MAC Sibling BM - BuþCy Alive and well No 100 822
2002 37/39 M/M SAA RIC MUD BM Thymoglobuline FluþfTBIþCy Alive and well No 100 887
2002 6/21 F/M SAA RIC MUD BM Thymoglobuline FluþfTBIþCy Alive and well No 100 909
2003 8/41 M/F Fanconi anemia RIC MUD BM Thymoglobuline FluþCy Alive, renal failure grade III No 100 954
2003 38/43 F/F SAA RIC MUD BM Thymoglobuline FluþfTBIþCy Alive,
hyperparathyroidism
No 100 955
2004 11/31 M/M SAA RIC MUD BM Thymoglobuline FluþfTBIþCy Alive and well No 100 1065
2005 13/17 F/F Sickle cell anemia MAC Sibling BM - BuþCy Alive, ovarian dysfunction No 100 1111
2006 9/40 F/F SAA RIC MUD PB Thymoglobuline FluþfTBIþCy Alive, neuropsychiatric
issues, EP
No 90 1166
2006 9/41 M/M SAA RIC MUD BM Thymoglobuline FluþfTBIþCy Alive and well No 100 1167
2007 11/0 M/F CGD RIC MMUD CB Thymoglobuline FluþTreo Alive, vision impairment No 100 1229
HSCT indicates hematopoietic stem cell transplantation; REC, recipient; DON, donor; WAS, Wiskott-Aldrich syndrome; ALD, adrenoleukodystrophy; SAA, severe aplastic anemia; CGD, chronic granulomatous disease; AGU,
aspartylglucosaminuria; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; BM, bone marrow; PB, peripheral blood; CB, cord blood;
Bu, busulfan; Cy, cyclophosphamide; Flu, ﬂudarabine; fTBI, fractionated total body irradiation; Treo, treosulphan; UPN, unique patient number; M, male; F, female.
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Figure 1. Chimerism patterns. Arrows indicate the time when immunosuppressive treatment was stopped for each patient. Patients UPN 527 and 652 still receive
immunosuppressive treatment.
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Table 2
Differences in Chimerism Pattern Fluctuations in MC Patients Between Time Periods Post-HSCT
0 to 24 Months Post-HSCT
(early)
48 to 72 Months Post-HSCT
(middle)
120 to 144 Months Post-HSCT
(late)
P Values
CD3: median (range) (n) 8.75 (6.41-16.72) (9) 2.8 (1-13.57) (10) 2.5 (1.25-3.75) (5) .006, early versus middle
CD19: median (range) (n) 5 (0.71-13.44) (9) 1.12 (0-5) (9) 1.5 (0.28-13-33) (5) .024, early versus middle
CD33: median (range) (n) 12.02 (0-25.31) (7) 2.6 (0.83-5.76) (6) 2.5 (1.25-7.48) (5) n.s.
HSCT indicates hematopoietic stem cell transplantation; MC, mixed chimerism; n, number of patients; n.s., not signiﬁcant.
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Most patients (22 of 25) were treated with anti-T cell antibodies as
serotherapy before HSCT, as described before [16]. Detailed information can
be found in Table 1. No signiﬁcant difference in dose of anti-T cell antibodies
were observed between DC and MC patients. Supportive care and graft-
versus-host disease (GVHD) prophylaxis was given according to institu-
tional guidelines and standard protocols as described in detail elsewhere
[17-22].Statistics
Data were analysed using Excel (Microsoft Corp, Redmond, WA) and
Prism (GraphPad, San Diego, CA) software. Parameters included were
recipient body mass index; recipient and donor gender; recipient and donor
age at HSCT; time post-HSCT; donor cell origin; matching of donor and
recipient (unrelated or sibling); CD3, CD19, hematopoietic stem cell (CD34),
NK cell (CD56), and total nucleated cell dose at HSCT; recipient and donor
blood types (ABO); conditioning regimen; GVHD prophylaxis; days post-
HSCT to discharge from hospital; thrombocyte recovery (ie, days post-
HSCT until blood thrombocyte count was 50  109/L for 5 consecutive
days); recipient and donor human leukocyte antigen (HLA) typing; acute
GVHD (aGVHD); chronic GVHD (cGVHD); diagnosis; anti-thymocyte glob-
ulin (ATG) dose; blood stream infection (BSI); donor lymphocyte infusion
therapy; cytomegalovirus, herpes simplex virus, and Epstein-Barr virus
mismatch; granulocyte colony-stimulating factor treatment; reduced
intensity conditioning versus myeloablative conditioning regimens; leuko-
cyte recovery (ie, days post-HSCT until blood absolute leukocyte count is
>0.2  109/L for 2 consecutive days); cytomegalovirus, herpes simplex
virus and varicella zoster virus re-activation; thrombocyte transfusions;
erythrocyte transfusion; neutrophil recovery (ie, days post-HSCT until blood
absolute neutrophil granulocyte count has reached >0.5  109/L blood for
2 consecutive days); and chimerism pattern ﬂuctuations.
Chimerism pattern ﬂuctuations were calculated for 3 ﬁxed periods post-
HSCT (0 to 24months, 48 to 72months, and 120 to 144months) for the 3 cell
lineages (CD3, CD19, and CD33) as follows: the sum of all changes in values
per period divided by the number of times chimerismwas measured within
the speciﬁc period.
Univariate analysis on all these parameters was performed using the
Mann-Whitney and Fisher Exact test. Despite small group sizes, we per-
formed a multivariate analysis of parameters found to be signiﬁcant in
univariate analysis (logistic regression). Statistical signiﬁcancewas set at P<
.05. Data in tables are presented as median values and range (minimum to
maximum) or as absolute numbers. In graphs, data are shown as percentage
recipient-derived cells.RESULTS
Chimerism Patterns in Patients with Stable MC
As depicted in Figure 1, all MC patients were stable over
time. For 4 patients (UPN 527, 539, 603, and 615) early data
on the CD33 cell lineage are lacking because chimerism
analysis prior to May 2002 did not include this cell lineage.
Additionally, for 2 patients (UPN 527 and 652), initial
chimerism data are missing because they were not yet
initiated in clinical routine at the time of HSCT (UPN 527) orTable 3
Differences in Chimerism Pattern Fluctuations in MC Patients Between Cell Lineag
CD3: Median (range) (n) CD19: Med
0-24 months post-HSCT (early) 8.75 (6.41-16.72) (9) 5 (0.71-
48-72 months post-HSCT (middle) 2.8 (1-13.57) (10) 1.12 (0-5)
120-144 months post-HSCT (late) 2.5 (1.25-3.75) (5) 1.5 (0.28-
HSCT indicates hematopoietic stem cell transplantation; MC, mixed chimerism; n,initially there were no suitable markers to distinguish
recipient and donor (UPN 652).
In general, for the majority of cases, chimerism pattern
ﬂuctuations of the 3 cell lineages followed each other. Fluc-
tuations in donor-to-recipient ratio were mostly seen during
the ﬁrst 24 months post-HSCT and, thereafter, the levels
tended to stabilize. Fluctuations in chimerism levels were
signiﬁcantly larger 0 to 24months post-HSCT as compared to
48 to 72 months post-HSCT for 2 cell lineages (P ¼ .024 for
CD19; P ¼ .006 for CD3; Table 2). Additionally, chimerism
ﬂuctuations between cell lineages in the same period post-
HSCT showed a signiﬁcantly higher ﬂuctuation in the CD3
compared to the CD19 cell lineage (P ¼ .008 for 0 to 24
months; P ¼ .050 for 48 to 72 months post-HSCT; Table 3).
Clinical Variables Associated with Stable MC
Mechanisms and factors that promote establishment of
stable MC are largely unknown. To identify potential factors,
we compared patients with stable MC to age-, diagnosis-,
gender- and time post-HSCT matched DC patients. Signiﬁ-
cant differences between the groups are outlined in Table 4.
Both donor age and type were associated with stable MC
development (median donor age: MC, 9 versus DC, 31 years;
P¼ .017; and sibling donor: MC, 9 of 12 versus DC, 2 of 13; P¼
.005). Additionally, median leukocyte recovery occurred
faster in the MC group than in the DC group (MC, 12 versus
DC, 16 days; P ¼ .038). Five DC patients (UPN 822, 887, 909,
955, and 1111) developed BSI post-HSCT, while none of the
MC patients did (MC, 0 of 12 versus DC, 5 of 13; P ¼ .039).
Conditioning regimens were also associated with devel-
opment of MC and DC. A regimen with cyclophosphamide
alone was associated with MC development (patients
receiving regimen: MC, 5 of 12 versus DC, 0 of 13; P ¼ .015).
Conversely, ﬂudarabine (Flu) and fractional total body irra-
diation (fTBI) were used more often in the DC group than
the MC group (Flu: MC, 3 of 12 versus DC, 9 of 13; P ¼ .047;
and fTBI: MC, 1 of 12 versus DC, 7 of 13; P ¼ .030). Finally,
no signiﬁcant differences for HLA types were found except
for the HLA-B18 allele, which was correlated with develop-
ment of DC, but not with MC (MC, 0 of 12 versus DC, 5 of 13;
P ¼ .039).
GVHD
Development of aGVHD was less prevalent in the MC
group compared with the DC group (MC, 3 of 12 versus DC,
9 of 13; P ¼ .047). Interestingly, the onset of aGVHD occurred
faster in the MC than the DC group (MC, 12  3.8 days versuses Post-HSCT
ian (range) (n) CD33: Median (range) (n) P Values
13.44) (9) 12.02 (0-25.31) (7) .008, CD3 versus CD19
(9) 2.6 (0.83-5.76) (6) .050, CD3 versus CD19
13-33) (5) 2.5 (1.25-7.48) (5) n.s.
number of patients; n.s., not signiﬁcant.
Table 4
Signiﬁcant Differences in Clinical Variables Between DC and MC Patients
MC DC P Values
No. patients 12 13
Origin of stem cells
Sibling/unrelated 9/3 2/11 .005
Conditioning
Only Cy/other 5/7 0/13 .015
fTBI/no fTBI 1/11 7/6 .030
Flu/no Flu 3/9 9/4 .047
Age of donor at HSCT, yr,
median (range) (n)
9 (0-50) (12) 31 (0-43) (12) .017
Days post-HSCT of aGVHD
occurrence median
(range) (n)
12 (11-18) (3) 41 (14-65) (9) .018
aGVHD development
(yes/no)
3/9 9/4 .047
Leukocyte recovery median
(range) (n)
12 (10-17) (12) 16 (9-23) (13) .038
BSI after HSCT (yes/no) 0/12 5/8 .039
HLA-B18 (yes/no) 0/12 5/8 .039
MC indicates mixed chimerism; DC, donor chimerism; HSCT, hematopoietic
stem cell transplantation; Cy, cyclophosphamide; Flu, ﬂudarabine; fTBI,
fractionated total body irradiation; aGVHD, acute graft-versus-host disease;
BSI, blood stream infection; HLA, human leukocyte antigen.
Table 5
Multivariate Analysis on MC Development
Odds Ratio 95% CI
odds Ratio
P Values
Model 1
Donor type (sibling/unrelated) 8.61 0.77-96.6 .065
Donor age 0.96 0.89-1.04 .31
Model 2
Donor type (sibling/unrelated) 19.5 1.64-250 .013
aGVHD development 0.11 0.009-1.36 .07
MC indicates mixed chimerism; CI, conﬁdence interval; aGVHD, acute graft-
versus-host disease.
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(UPN 603, 652, and 921) developed aGVHD grade 1 within
18, 12, and 11 days post-HSCT, respectively. One of these
patients alsowent on to develop limited cGVHD (UPN 652) at
342 days. No higher aGVHD grade was observed in the MC
group. No chimerism data exist for the time around the
occurrence of GVHD (Figure 1). In the DC group, 7 of 13
patients developed aGVHD grade 1 (UPN 707b, 731, 822, 909,
954, 1166, and 1167) within median 41 days post-HSCT
(range, 14 to 65 days). Two DC patients developed aGVHD
grade 2 (UPN 1065, liver and gastrointestinal tract; and UPN
1111, gastrointestinal tract) within 59 and 37 days post-HSCT
respectively. Additionally, 2 DC patients developed limited
cGVHD (UPN 822 and 954) at 519 and 483 days post-HSCT.
Outcome
In the MC group, 12 of 13 patients are well and their
underlying diseases are corrected by the HSCT. The remain-
ing MC patient (UPN 652), transplanted because of b-thal-
assemia major, is well but still in need of erythrocyte
transfusions. All patients in the DC group are alive and well
with their underlying diseases corrected. There was no
difference in the rate of post-HSCT complications between
the MC and DC groups.
Multivariate Analysis
Because parameters that were found signiﬁcant in
univariate analysis, eg, donor type, donor age, conditioning
treatment, and aGVHD development, most likely are associ-
ated, we performed a multivariate analysis. As cyclophos-
phamide alone was given to none of the DC patients, we
could not include this parameter in the multivariate analysis.
Also, because the patient material was small, the analysis
was divided in 2 parts. In the ﬁrst, donor type and donor age
were analyzed for the impact on MC development and in the
second, donor type and aGVHD development were analyzed
for MC development. Results of the multivariate analysis are
depicted in Table 5.
DISCUSSION
Long-lasting, stable MC is a rarely documented phenom-
enon after HSCT. Although some case reports with long-termfollow-up of some stable MC patients exist [8,10], this is the
ﬁrst report with lineage speciﬁc chimerism analysis with this
many nonmalignant patients over an extended period of
time post-HSCT. To date, the mechanisms regulating the
generation of a stable mixed chimera, as well as the potential
clinical impact on the patient are largely unknown. Under-
standing these factors is important as it could have an impact
on future HSCT protocols.
All 12 MC patients studied were stable, mixed chimeras
over a period of at least 60 months (range, 5 to 16.5 years) in
the 3 different cell lineages (CD3, CD19, and CD33). Interest-
ingly, ﬂuctuations within cell lineages were signiﬁcantly
higher at 0 to 24 months post-HSCT compared to 48 to 72
months post-HSCT (Table 2). Moreover, the CD3 lineage
ﬂuctuated signiﬁcantly more than the CD19 lineage within
the different time periods (Table 3), suggesting a CD3
cell-mediated response between donor and recipient cells
due to the inefﬁcient recipient removal after reduced inten-
sity conditioning treatment [23].
A number of signiﬁcant differences betweenpatients with
MC and DC were identiﬁed and could be used as predictive
markers. Donor age has previously been associated with the
development of GVHD after HSCT [24]. Several earlier studies
could not ﬁnd an association between donor age and short
term MC development [25-27]. In this study, a 3-fold higher
donor age was found in the DC group compared with the
stable MC group (P ¼ .017). A HSCT with a younger donor,
which contains presumably more naïve immune cells [28],
might to a higher degree lead to a state of clinical tolerance
between donor and recipient cells, possibly through central
thymic tolerance [29]. This is substantiated by the fact that
aGVHD was primarily observed in the DC group (MC, 3 of 12
versus DC, 9 of 13; P ¼ .047). The prevalence of aGVHD has
earlier been associated with the development of DC in
patients with nonmalignant diseases [4,27,30].
Furthermore, the donor type, ie, sibling or matched
unrelated donor, was also found to be a signiﬁcant factor as
sibling donors were more frequent in the MC group (MC, 9 of
12 versus DC, 2 of 13; P ¼ .005). Because sibling donor cells
are a closer HLA and minor histocompatibility antigen match
than unrelated donor cells, they will be less prone to induce
immune-mediated killing of recipient cells. The difference in
graft source has been shown previously to be associated with
the incidence of GVHD [31]. A multivariate analysis on the
effect of aGVHD development together with donor type on
MC development demonstrated that donor type was asso-
ciated with MC development (P ¼ .013). A statistical trend
was seen towards an association between aGVHD and MC
development (P ¼ .07). In this study, the tolerogenic milieu
created after sibling donor HSCT therefore seems to increase
the likelihood of long-lasting MC development. However, in
our material donor age was correlated to donor type as most
sibling donors were younger donors (median, 12 years) and
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.003). Multivariate analysis of donor type and age on MC
development displayed a trend towards an association with
donor type (P¼ .06), but not to donor age (P¼ .31). Therefore,
we conclude that the effect of donor age onMC development
is most likely associated with the donor type.
MC patients were conditioned with milder regimens than
the patients in the DC group: 5 of 12 MC patients received
only cyclophosphamide whereas no DC patients received
cyclophosphamide (P ¼ .015). The use of fTBI or Flu in the
treatment, regardless of other drugs given, was instead
signiﬁcantlymore prevalent in the DC patient group (P¼ .030
and P ¼ .047, respectively). We have previously shown
a correlation between donor T cell chimerism and fTBI in
patients with malignant diseases [32].
The HLA-B18 allele was signiﬁcantly more prevalent in
the DC group (MC, 0 of 12 versus DC, 5 of 13; P ¼ .039). All
patients were heterozygous for the allele. It is not clear why
HLA-B18 would have such an inﬂuence on MC development.
Even though this allele has been linked to an increased risk
for posttransplantation lymphoproliferative disease after
solid organ transplantation [33], it has not yet been linked to
chimerism.
Based on the range of clinically assessed parameters, our
data suggests that MC is not necessarily linked to a worse
prognosis as compared to patients with DC. Although leuko-
cyte recovery was reached slightly earlier for MC patients
than DC patients (MC, 12 days versus DC, 16 days; P ¼ .038),
various other parameters related to hematopoietic reconsti-
tution (eg, thrombocyte recovery and neutrophil recovery)
were not found to be signiﬁcantly different between the
groups. Finally,MCpatients had a lower risk of developing BSI
than DC patients (MC, 0 of 12 versus DC, 5 of 13; P ¼ .039). In
combination with the higher prevalence of aGVHD in the DC
group, the higher risk of BSI in DC patients is a good
demonstration of the comorbidity of aGVHD and infections
resulting in BSI for patients post-HSCT, as has beenpreviously
suggested [34,35]. The increased occurrence of BSI in the DC
group might be explained by that their immune systems are
primarily composed of newly developing cells that still
require priming, whereas the MC patients maintain their
recipient memory cells for immediate targeted responses.
In order to draw signiﬁcant conclusions usable for clinical
use, a larger study with more MC and DC patients should be
completed.Multiple centerswouldhave tobe involved for such
a large study since stable MC occurrence is, as stated before,
relatively rare. Amore detailed picture of stableMCoccurrence
may well beneﬁt HSCT patients’ treatment worldwide.ACKNOWLEDGMENTS
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